HomeTrialNCT06122779
🔬NCT06122779Phase 2RECRUITING

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment208 participants
Primary Completion
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-04-11 04:08:14.746522+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.